Example searches

ENZ Enzo Biochem, Inc.

All ENZ filings Filing statistics SEC Website
Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Company profile

Ticker
ENZ
Exchange
NYSE
CEO
Elazar Rabbani
Employees
Incorporated in
New York
Location
New York
Fiscal year end
Jul 31
Sector
Health Technology > Biotechnology
Industry (SEC)
Services - Medical Laboratories
Quest Diagnostics • Laboratory Corp of America • RadNet • Guardant Health • Genomic Health • Invitae • Natera • Veracyte • American Shared Hospital Services • CareDx ...
SEC CIK
0000316253
Corporate docs
Articles of Incorporation & Bylaws
IRS number
132866202

ENZ stock data

(
)

Calendar

10 Jun 19
22 Aug 19
31 Jul 20

News

Company financial data Financial data

Chart ENZ financial data
Download latest Excel data (2019 Q3) View latest Excel data (2019 Q3)
Quarter (USD) Apr 19 Jan 19 Oct 18 Jul 18
Revenue 19.66M 19.33M 21.26M 26.46M
Net income 22.27M -8.41M -5.98M -5.76M
Diluted EPS 0.47 -0.18 -0.13 -0.12
Net profit margin 113% -43.50% -28.13% -21.79%
Operating income 22.27M -8.89M -5.98M -5.71M
Net change in cash 22.07M -10.8M -7.26M -2.52M
Cash on hand 64.05M 41.98M 52.78M 60.04M
Cost of revenue 14.36M 14.75M 14.24M
Annual (USD) Jul 18 Jul 17 Jul 16 Jul 15
Revenue 104.71M 107.8M 102.77M 97.6M
Net income -10.32M -2.5M 45.29M -2.29M
Diluted EPS -0.22 -0.05 0.97 -0.05
Net profit margin -9.86% -2.32% 44.06% -2.34%
Operating income -12.16M -3.15M 46.85M -1.21M
Net change in cash -4.13M -3.61M 49.67M 654K
Cash on hand 60.04M 64.17M 67.78M 18.11M
Cost of revenue 45.4M 42.86M 39.59M

Financial data from company earnings reports

Financial report summary

?
Competition
WaferGen Bio-systems
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: al, attorney, conclusion, contend, decide, dismissed, error, formally, improperly, lesser, occupancy, overpaid, professional, promulgated, PTAB, reached, real, recoup, resolving, seventeen, toreimbursement, twointer, variance, withdrew
Removed: construction, denied, denying, disagree, docketed, granting, installment, institution, inter, invalidated, machinery, motion, notice, October, opening, partial, petition, proceeding, PTO, rehearing, request, requesting, slightly, Trademark
From filing 10-Q 2019 Q3

Financial reports

View all
10-Q
2019 Q3
Quarterly report
10 Jun 19
10-Q
2019 Q2
Quarterly report
11 Mar 19
10-Q
2019 Q1
Quarterly report
10 Dec 18
10-K
2018 FY
Annual report
15 Oct 18
10-Q
2018 Q3
Quarterly report
11 Jun 18
10-Q
2018 Q2
Quarterly report
12 Mar 18
10-Q
2018 Q1
Quarterly report
7 Dec 17
10-K
2017 FY
Annual report
27 Sep 17
10-Q
2017 Q3
Quarterly report
8 Jun 17
10-Q
2017 Q2
Quarterly report
13 Mar 17

Current reports

View all
8-K
Other Events
5 Aug 19
8-K
Enzo Biochem Announces Key Transformative Initiatives to Propel and Accelerate Growth In its Lab Business
12 Jul 19
8-K
Other Events
21 Jun 19
8-K
Enzo Biochem Reports Fiscal Third Quarter and Nine Months Operating Results
10 Jun 19
8-K
Enzo Biochem Inc. Announces Issuance of United States Patent for Treatment of Liver Cancer Using Ozanimod
13 May 19
8-K
Entry into a Material Definitive Agreement
22 Apr 19
8-K
Reports Progress on Its Investments and Strategic Goals
11 Mar 19
8-K
Entry into a Material Definitive Agreement
11 Feb 19
8-K
Departure of Directors or Certain Officers
3 Jan 19
8-K
Enzo Biochem Reports Fiscal 2019 First Quarter Results
10 Dec 18

Registration and prospectus

View all
S-8
Registration of securities for employees
13 Aug 18
S-3
Shelf registration
1 Sep 17
S-3/A
Shelf registration (amended)
28 Oct 16
S-3
Shelf registration
1 Sep 16
424B5
Prospectus supplement for primary offering
31 Dec 14
S-8
Registration of securities for employees
25 Jun 14
S-3
Shelf registration
1 Aug 13
424B5
Prospectus supplement for primary offering
28 Mar 13
424B5
Prospectus supplement for primary offering
29 Jun 12
S-8
Registration of securities for employees
9 Feb 11

Proxies

View all
DEF 14A
Definitive proxy
21 Nov 18
DEF 14A
Definitive proxy
22 Nov 17
DEFA14A
Additional proxy soliciting materials
22 Nov 17
DEF 14A
Definitive proxy
23 Nov 16
DEFA14A
Additional proxy soliciting materials
23 Nov 16
DEFA14A
Additional proxy soliciting materials
30 Dec 15
DFAN14A
Additional proxy materials by non-management
29 Dec 15
DEFA14A
Additional proxy soliciting materials
28 Dec 15
DEFA14A
Additional proxy soliciting materials
23 Dec 15
DEFA14A
Additional proxy soliciting materials
23 Dec 15

Other

View all
EFFECT
Notice of effectiveness
15 Sep 17
CORRESP
Correspondence with SEC
13 Sep 17
UPLOAD
Letter from SEC
12 Sep 17
EFFECT
Notice of effectiveness
3 Nov 16
CORRESP
Correspondence with SEC
2 Nov 16
CORRESP
Correspondence with SEC
28 Oct 16
UPLOAD
Letter from SEC
12 Oct 16
CORRESP
Correspondence with SEC
7 Oct 16
CORRESP
Correspondence with SEC
30 Sep 16
UPLOAD
Letter from SEC
29 Sep 16